ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1268

Development of the LupusCoach Chatbot: Results of a Focus Group

Leila Khalili1, Pooja Desai2, Maya Souvignier2, Adrienne Pichon2, Stephen Suh3, Alberto Nordmann-Gomes2, Lena Mamykina2 and Anca Askanase1, 1Columbia University Medical Center, New York, NY, 2Columbia University Irving Medical Center, New York, NY, 3Columbia University Irving Medical Center, New York City, NY

Meeting: ACR Convergence 2025

Keywords: Data Management, Qualitative Research, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (1248–1271) Patient Outcomes, Preferences, & Attitudes Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Self-management education and coaching are successful interventions for managing chronic health conditions. However, accessibility of in-person coaching is limited; digital coaching is available and has been tested in patients with multiple chronic health conditions, but not in systemic lupus erythematosus (SLE). Building on previous work in collaboration with the biomedical informatics team, the CUIMC Lupus Center team developed a lupus chatbot, LupusCoach. The fully scripted chatbot focuses on two areas: 1) weekly educational goal setting for lupus patients that includes lupus specific, lupus clinical trials, and general health information and 2) weekly health management goal setting related to lupus. Here we describe the qualitative feedback of two focus groups evaluating the content and goals for LupusCoach.

Methods: Ten diverse lupus patients (all patients met the 2019 ACR/EULAR criteria for SLE) were selected via convenience sampling to give feedback on the chatbot educational content and goals. We conducted two focus groups remotely using video-conferencing software. The focus groups were audio recorded and transcribed verbatim. Reflective thematic analysis was conducted using the NVIVO software.

Results: Thematic analysis across patients from both focus groups identified several main themes relating to participant background and chatbot feedback. Participant background themes included connection between patients and providers, participants’ individual experiences with lupus, and strategies for lupus management (Table 1). Themes relating to chatbot feedback included desired features and capabilities, experiences with technology, input on goals and action plans, discussion about informational messages, and user expectations of technology (Table 2). Based on these themes, we made adjustments to LupusCoach, specifically by tailoring action plans to different levels of effort. An on-line support community forum was requested, and therefore additional resources for lupus patients were listed on the accompanying FAQ/further information website for LupusCoach.

Conclusion: Overall, patients gave positive feedback both on the contents and goals of LupusCoach. The next step is to beta-test the chatbot and survey a larger group of 10-20 patients, using pre/posttest method, questionnaires, and surveying for satisfaction.

Supporting image 1Table 1. Description of Themes Relating to Participant Background and Experience

Supporting image 2Table 2. Description of Themes Relating to Chatbot Feedback


Disclosures: L. Khalili: None; P. Desai: None; M. Souvignier: None; A. Pichon: None; S. Suh: None; A. Nordmann-Gomes: None; L. Mamykina: None; A. Askanase: AbbVie, 2, Amgen, 2, 5, AstraZeneca, 2, 5, Aurinia, 2, 5, BMS, 2, 5, Eli Lilly, 5, Genentech, 2, 5, GSK, 2, 5, Idorsia, 2, 5, Janssen, 2, NKARTA, 5, Pfizer, 2, Sanofi, 5, UCB, 2, 5.

To cite this abstract in AMA style:

Khalili L, Desai P, Souvignier M, Pichon A, Suh S, Nordmann-Gomes A, Mamykina L, Askanase A. Development of the LupusCoach Chatbot: Results of a Focus Group [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/development-of-the-lupuscoach-chatbot-results-of-a-focus-group/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/development-of-the-lupuscoach-chatbot-results-of-a-focus-group/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology